Germany: Third party interventions to ex parte proceedings

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: Third party interventions to ex parte proceedings

In a decision (BGH X ZB 4/14, "Verdickerpolymer II"), the German Federal Court of Justice (BGH) has resolved the question of third party interventions to ex parte proceedings. The BGH found that there is no legal basis for third party interventions to ex parte proceedings of the patent proprietor requesting reinstatement even when the third party is sued for infringement of the patent in suit.

The German part of European patent EP 682 094, maintained in amended form after opposition proceedings, lapsed in Germany because the proprietor failed to pay the publication fee and provide a German translation of the amended patent within the legal deadlines. The patent proprietor requested reinstatement and a third party being sued for infringement of the patent in suit requested intervention to the reinstatement proceedings.

Section 59(2) PatG provides a legal basis for third party interventions to inter-partes opposition proceedings in the case of pending infringement or declaratory proceedings. Section 44(2) PatG explicitly excludes third party interventions to ex-parte grant proceedings.

The BGH found that the lack of a provision concerning a third party intervention to ex-parte proceedings if the third party is sued for infringement of the patent in suit is not considered as an unplanned legal loophole. The restrictive character of the provisions for third party interventions indicates a conclusive nature that cannot be generalised. It is emphasised that reinstatement proceedings are ancillary proceedings conducted in the course of main proceedings and if third party interventions to main proceedings are only allowed under exceptional circumstances similar hurdles must apply for associated ancillary proceedings.

With respect to decision BGH X ZB 26/70 "Hopfenextrakt", wherein an opponent was allowed to participate in reinstatement proceedings, it is emphasised that this decision has been issued under the previous law and is based on the prerequisite that opposition proceedings are conducted as part of grant proceedings. The decision is not considered applicable when opposition proceedings and grant proceedings are independent from each other.

It has been clarified that a third party intervention to ancillary proceedings is only allowable if the third party is involved in the corresponding main proceedings. Furthermore, the existing provisions on third party interventions are considered conclusive.

Tim Pust


Maiwald Patentanwalts GmbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

AG Barr acquires drinks makers Fentimans and Frobishers, in deals worth more than £50m in total
Tarun Khurana at Khurana & Khurana says corporates must take the lead if patent filing activity is to truly translate into innovation
Michael Moore, head of legal at Glean AI, discusses how in-house IP teams can use AI while protecting enforceability
Counsel for SEP owners and implementers are keeping an eye on the case, which could help shape patent enforcement strategy for years to come
Jacob Schroeder explains how he and his team secured victory for Promptu in a long-running patent infringement battle with Comcast
After Matthew McConaughey registered trademarks to protect his voice and likeness against AI use, lawyers at Skadden explore the options available for celebrities keen to protect their image
The Via members, represented by Licks Attorneys, target the Chinese company and three local outfits, adding to Brazil’s emergence as a key SEP litigation venue
The firm, which has revealed profits of £990,837, claims it is the disruptive force in the IP-legal industry
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date
Arun Hill at Clarivate assesses the Top 100 Global Innovators 2026 list, including why AI has assumed a strategic importance for innovation
Gift this article